Boehringer Gains FDA Approval of COPD Treatment
Boehringer Ingelheim announces FDA approval of Stiolto Respimat inhaler for the treatment of COPD.
Boehringer Ingelheim announced on May 26, 2015 the approval of Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for chronic obstructive pulmonary disease (COPD), including chronic bronchitis, and/or emphysema. The once-daily treatment was found to improve lung function on a greater scale when compared to the use of tiotropium and olodaterol alone in patients with COPD ranging in severity.
“A recent review of landmark studies indicates that loss of lung function is more accelerated in the early stages of COPD. While no treatment slows the rate of decline, maintenance treatment with Stiolto Respimat initiated at the time of diagnosis will help healthcare providers with their goal of improving lung function,” said Danny McBryan, MD, vice-president, clinical development and medical affairs, respiratory, Boehringer Ingelheim Pharmaceuticals, in a press release.
Source: Boehringer Ingelheim
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
